Wall Street analysts expect that Gamida Cell Ltd (NASDAQ:GMDA) will report earnings of ($0.39) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Gamida Cell’s earnings. The firm is expected to announce its next earnings report on Monday, February 24th.
On average, analysts expect that Gamida Cell will report full-year earnings of ($1.12) per share for the current year. For the next financial year, analysts forecast that the firm will post earnings of ($1.44) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Gamida Cell.
Gamida Cell (NASDAQ:GMDA) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.07.
Shares of GMDA stock traded up $0.02 during trading hours on Friday, hitting $4.56. 4,637 shares of the company were exchanged, compared to its average volume of 34,060. The business has a 50 day moving average of $4.70 and a two-hundred day moving average of $4.43. The company has a current ratio of 7.61, a quick ratio of 7.60 and a debt-to-equity ratio of 0.09. Gamida Cell has a 52 week low of $2.93 and a 52 week high of $15.00. The company has a market capitalization of $111.06 million, a PE ratio of -0.43 and a beta of 1.64.
A number of institutional investors have recently added to or reduced their stakes in GMDA. Royal Bank of Canada bought a new position in Gamida Cell in the second quarter valued at $71,000. Phoenix Holdings Ltd. bought a new position in Gamida Cell in the third quarter valued at $121,000. EcoR1 Capital LLC bought a new position in Gamida Cell in the second quarter valued at $265,000. Millennium Management LLC grew its position in Gamida Cell by 4.6% in the third quarter. Millennium Management LLC now owns 69,077 shares of the company’s stock valued at $299,000 after purchasing an additional 3,017 shares in the last quarter. Finally, Noked Capital LTD bought a new position in Gamida Cell in the second quarter valued at $1,035,000. 23.87% of the stock is owned by institutional investors and hedge funds.
Gamida Cell Company Profile
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Recommended Story: Market Perform
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.